About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness ...
Dec 10, 2024
0
1
A study led by the group of Didier Trono at EPFL has revealed a crucial survival tactic employed by cancer cells. The scientists have identified a group of proteins, known as "KRAB zinc finger proteins" (KZFPs), that help ...
Feb 12, 2024
0
0
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), led by Assistant Professor Anand Jeyasekharan, has discovered a unique combination of oncogenes ...
Jul 19, 2023
0
0
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people ...
May 25, 2022
0
6
Newer therapies are outpacing the current treatment for diffuse large B cell lymphoma, according to data that scientists will deliver from two major clinical trials at the American Society of Hematology (ASH) annual meeting ...
Dec 10, 2021
0
1
The National Institute for Health and Care Excellence (NICE) has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.
Aug 21, 2020
0
1
A team of researchers investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Jul 24, 2020
0
2
The National Institute for Health and Care Excellence (NICE) has not recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.
Mar 12, 2020
0
1
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
Dec 10, 2013
0
0
Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing ...
Aug 1, 2013
0
0
Diffuse large B-cell lymphoma (DLBL, DLBCL, or DLCL) is a type of aggressive non-Hodgkin lymphoma. It accounts for approximately 40% of lymphomas among adults. The median age at diagnosis is 70 years, but it also occurs in children and young adults. As with most non-Hodgkin lymphomas, there is a male predominance, although primary cutaneous diffuse large B cell lymphoma is more common in women. Of all cancers involving the same class of blood cell, 31% of cases are DLBL.
This text uses material from Wikipedia licensed under CC BY-SA
